GSKure uses the novel SCI strategy for drug design that has a significant advantage for clinical practice.
Professor Hagit Eldar-Finkelman, from Tel Aviv University, conducted pioneering studies in developing GSK-3
inhibitors and the therapeutic use in treating human disease.
GSKure ia an IP based company dedicated to implicate its theraprotic approach for treating brain desires.
To enhance our mission we are in search for partners to join our efforts.